Stanford spinout’s latest deal looks to unlock new fix for sickle cell disease

The initial Stanford research, studying how to make more bone marrow more receptive to gene therapies and stem cell transplants and less toxic for patients, was backed by nearly $23 million in grants from California's stem cell research funding agency.